Optimization of the freezing process for hematopoietic progenitor cells: effect of precooling, initial dimethyl sulfoxide concentration, freezing program, and storage in vapor‐phase or liquid nitrogen on in vitro white blood cell quality

Dijkstra‐Tiekstra, Margriet J.; Setroikromo, Airies C.; Kraan, Marcha; Gkoumassi, Effimia; Wildt‐Eggen, J. de

doi:10.1111/trf.12756

Cited by 12 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dijkstra-Tiekstra et al [60] performed a study using precooled DMSO and precooled white blood cells (WBCs). Results showed that precooling has a minimal effect on WBC recovery.…”

Section: Additional Considerationsmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

show abstract

“…Dijkstra-Tiekstra et al [60] performed a study using precooled DMSO and precooled white blood cells (WBCs). Results showed that precooling has a minimal effect on WBC recovery.…”

Section: Additional Considerationsmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Current methods of optimizing cryopreservation solutions most often use empirical methods, by testing a given composition and cooling rate and measuring post‐thaw recovery (Conrad et al ., ; Dijkstra‐Tiekstra et al ., ; Dong et al ., ; Freimark et al ., ; Kearney et al , ). Our studies show that optimization of freezing solutions can be performed using a DE algorithm.…”

Section: Discussionmentioning

confidence: 99%

“…Freezing solution composition also influences cell survival (Mazur, ), and changing the composition of the cryopreservation solution may change the cooling rate at which optimum survival is observed. Cryopreservation protocols are most often determined empirically by changing the composition and cooling rate until the desired outcome is obtained (Conrad et al ., ; Dijkstra‐Tiekstra et al ., ; Dong et al ., ; Freimark et al ., ; Kearney et al , ). This process is typically expensive, time‐consuming and may not result in an optimized protocol.…”

Section: Introductionmentioning

confidence: 99%

Algorithm-driven optimization of cryopreservation protocols for transfusion model cell types including Jurkat cells and mesenchymal stem cells

Pollock

Budenske

McKenna

et al. 2016

J Tissue Eng Regen Med

View full text Add to dashboard Cite

This investigation describes the use of a differential evolution (DE) algorithm to optimize cryopreservation solution compositions and cooling rates for specific cell types. Jurkat cells (a lymphocyte model cell type) and mesenchymal stem cells (MSCs) were combined with non-DMSO solutions at concentrations dictated by a DE algorithm. The cells were then frozen in 96-well plates at DE algorithm-dictated cooling rates in the range 0.5–10°C/min. The DE algorithm was iterated until convergence resulted in identification of an optimum solution composition and cooling rate, which occurred within six to nine generations (seven to 10 experiments) for both cell types. The optimal composition for cryopreserving Jurkat cells included 300 mM trehalose, 10% glycerol and 0.01% ectoine (TGE) at 10°C/min. The optimal composition for cryopreserving MSCs included 300 mM ethylene glycol, 1 mM taurine and 1% ectoine (SEGA) at 1°C/min. High-throughput concentration studies verified the optimum identified by the DE algorithm. Vial freezing experiments showed that experimental solutions of TGE at 10°C/min resulted in significantly higher viability for Jurkat cells than DMSO at 1°C/min, while experimental solutions of SEGA at 10°C/min resulted in significantly higher recovery for MSCs than DMSO at 1°C/min; these results were solution- and cell type-specific. Implementation of the DE algorithm permits optimization of multicomponent freezing solutions in a rational, accelerated fashion. This technique can be applied to optimize freezing conditions, which vary by cell type, with significantly fewer experiments than traditional methods.

show abstract

“…Sputtek et al [87] reported that the cooling rate range can vary from 1 to 5 K/ min. Also, the recovery of white blood cell (WBC) recovery was found to be superior in slow rate freezing to fast rate freezing [88]. After the introduction of stem cell storage in liquid nitrogen, risks for microbial contamination of the products concluded with the usage of vapor phase for storage.…”

Section: Hematopoietic Progenitor Cell and Umbilical Cord Blood Cryopmentioning

confidence: 99%

Hematopoietic Stem Cell Source and Storage

Bozdağ¹,

İlhan²

2015

Progress in Stem Cell Transplantation

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation HSCT , has been accepted as a feasible treatment option that prolongs survival in hematological malignancies. Stem cell choice during hematopoietic stem cell transplantation can differ according to the experience of physicians, mostly treated hematological diseases in the centers or ongoing clinical trials. In this chapter we will discuss the advantages and disadvantages of three stem cell sources peripheral blood, bone marrow and umbilical cord blood.

show abstract

Optimization of the freezing process for hematopoietic progenitor cells: effect of precooling, initial dimethyl sulfoxide concentration, freezing program, and storage in vapor‐phase or liquid nitrogen on in vitro white blood cell quality

Cited by 12 publications

References 22 publications

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Algorithm-driven optimization of cryopreservation protocols for transfusion model cell types including Jurkat cells and mesenchymal stem cells

Hematopoietic Stem Cell Source and Storage

Contact Info

Product

Resources

About